我们旨在揭示表皮生长因子受体（EGFR）的真实状态 mutations  in  Chinese  patients  with  non-small
cell lung  cancer (NSCLC) after 肺 resections. 697例中国人手术切除的新鲜肿瘤样本的EGFR突变
NSCLC  patients  were  analyzed  by  扩增难治性突变系统（ARMS）。 Correlations between 表皮生长因子mutation hotspots and clinical features 是also explored.

Brain metastasis (BM) is a leading cause of death in 耐心with 非小cell 肺cancer (NSCLC). 表皮生长因子mutations in primary 非小细胞肺癌lesions have
been associated 与sensitivity to 表皮生长因子tyrosine kinase inhibitor (TKI). Therefore, it has become important to understand 表皮生长因子mutation status in
BM lesions of NSCLC, and its clinical implications. BM samples of 136 非小细胞肺癌耐心from South China, in which 15 had paired primary 肺tumors, 是retrospectively 分析对于EGFR mutation by amplification mutation refractory system (ARMS).

表皮生长因子受体的治疗 （EGFR）酪氨酸抑制剂（EGFR-TKIs）具有刺激作用 outcomes  for  advanced  non-small  cell  lung  cancer(NSCLC)  patients  with  EGFR  mutations.Pleural effusion is a common complication of NSCLC. We compared direct DNA sequencing and ADx Amplification Refractory Mutation System (ADx-ARMS) to detect 表皮生长因子mutations in malignant pleural effusion samples. 

Accurate determination of anaplastic lymphoma kinase (ALK) rearrangements is critical in identifying ALK-positive 耐心对于targeted therapy in 非小-cell 肺cancer (NSCLC).Fluorescence in situ hybridization(FISH) is the current standard method to detect ALK rearrangements but is technically challenging and costly.

To investigate PIK3CA mutation in 中文耐心with 肺squamous 细胞carcinoma (LSCC) 并探索他们的关系
与clinicopathological profiles.

To evaluate the diagnostic value of a novel fully automated immunohistochemistry (IHC) assay 对于detection of anaplastic
lymphoma kinase (ALK) fusion in a large number of ALK-positive 肺adenocarcinoma (ADC) patients.